<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259428</url>
  </required_header>
  <id_info>
    <org_study_id>EFC3153</org_study_id>
    <secondary_id>SR33589B</secondary_id>
    <nct_id>NCT00259428</nct_id>
  </id_info>
  <brief_title>EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)</brief_title>
  <acronym>EURIDIS</acronym>
  <official_title>EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus
      rhythm after electrical, pharmacological or spontaneous conversion of atrial
      fibrillation/atrial flutter (AF/AFL).

      To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.

      To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of
      AF/AFL recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, parallel arm, placebo-controlled, multicentre, multinational, phase
      III study.

      To be eligible, patients must be in normal sinus rhythm at randomisation and must have an
      ECG-documented history of recent AF/AFL reverted to normal sinus rhythm by electrical,
      pharmacological or spontaneous conversion
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study is the time from randomisation to first documented AF/AFL recurrence</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- AF/AFL related symptoms collected at the time of ECG/TTEM recording,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- mean ventricular rate during AF/AFL at first recorded AF/AFL recurrence (12-lead ECG or TTEM)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- time from presumed study drug near steady state defined as D5 midnight to first documented AF/AFL recurrence as indicated by ECG/TTEM recording.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">615</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Dronedarone 400mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dronedarone 400mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone (SR33589)</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Dronedarone 400mg bid</arm_group_label>
    <other_name>MultaqÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of either sex aged 21 years or more, in sinus rhythm for at least 1 hour at
             the time of randomization and with at least one ECG-documented AF/AFL episode in the
             last 3 months.

        Exclusion Criteria:

          -  MAIN CRITERIA (non-exhaustive list, see protocol for details):

        Women of childbearing potential without adequate birth control, Pregnant women,
        Breastfeeding women, Congestive heart failure NYHA class III or IV, Conditions which
        increase the risk of severe antiarrhythmic drug side effects, Severe associated conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD Clinical study director (CSD)</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi- Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 Sep 6;357(10):987-99.</citation>
    <PMID>17804843</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2005</study_first_submitted>
  <study_first_submitted_qc>November 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>February 8, 2010</last_update_submitted>
  <last_update_submitted_qc>February 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>ICD study director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Atrial Flutter</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Anti-Arrhythmia agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

